Literature DB >> 29273499

Combination Therapy Is the New Gene Therapy?

Giuseppe Ronzitti1, Federico Mingozzi2.   

Abstract

Mesh：

Year:  2017        PMID： 29273499      PMCID： PMC5763149          DOI： 10.1016/j.ymthe.2017.12.008

Source DB:  PubMed          Journal:  Mol Ther        ISSN： 1525-0016            Impact factor:   11.454


× No keyword cloud information.
  17 in total

Review 1.  Can immunosuppression be stopped after liver transplantation?

Authors:  Pierre-Alain Clavien; Xavier Muller; Michelle L de Oliveira; Philipp Dutkowski; Alberto Sanchez-Fueyo
Journal:  Lancet Gastroenterol Hepatol       Date:  2017-03-28

Review 2.  Host-virus interactions in hepatitis B virus infection.

Authors:  Luca G Guidotti; Masanori Isogawa; Francis V Chisari
Journal:  Curr Opin Immunol       Date:  2015-07-15       Impact factor: 7.486

Review 3.  Foxp3+ regulatory T cells in the control of experimental CNS autoimmune disease.

Authors:  Richard A O'Connor; Stephen M Anderton
Journal:  J Neuroimmunol       Date:  2008-01       Impact factor: 3.478

4.  Sirolimus-based graft-versus-host disease prophylaxis promotes the in vivo expansion of regulatory T cells and permits peripheral blood stem cell transplantation from haploidentical donors.

Authors:  J Peccatori; A Forcina; D Clerici; R Crocchiolo; L Vago; M T L Stanghellini; M Noviello; C Messina; A Crotta; A Assanelli; S Marktel; S Olek; S Mastaglio; F Giglio; L Crucitti; A Lorusso; E Guggiari; F Lunghi; M Carrabba; M Tassara; M Battaglia; A Ferraro; M R Carbone; G Oliveira; M G Roncarolo; S Rossini; M Bernardi; C Corti; M Marcatti; F Patriarca; M Zecca; F Locatelli; C Bordignon; K Fleischhauer; A Bondanza; C Bonini; F Ciceri
Journal:  Leukemia       Date:  2014-06-04       Impact factor: 11.528

Review 5.  Inhibitor development in haemophilia B: an orphan disease in need of attention.

Authors:  Donna DiMichele
Journal:  Br J Haematol       Date:  2007-08       Impact factor: 6.998

6.  Insulin B chain 9-23 gene transfer to hepatocytes protects from type 1 diabetes by inducing Ag-specific FoxP3+ Tregs.

Authors:  Mahzad Akbarpour; Kevin S Goudy; Alessio Cantore; Fabio Russo; Francesca Sanvito; Luigi Naldini; Andrea Annoni; Maria Grazia Roncarolo
Journal:  Sci Transl Med       Date:  2015-05-27       Impact factor: 17.956

7.  Assessment of toxicity and biodistribution of recombinant AAV8 vector-mediated immunomodulatory gene therapy in mice with Pompe disease.

Authors:  Gensheng Wang; Sarah P Young; Deeksha Bali; Julie Hutt; Songtao Li; Janet Benson; Dwight D Koeberl
Journal:  Mol Ther Methods Clin Dev       Date:  2014-06-11       Impact factor: 6.698

8.  Differential Regulation of Self-reactive CD4+ T Cells in Cervical Lymph Nodes and Central Nervous System during Viral Encephalomyelitis.

Authors:  Carine Savarin; Cornelia C Bergmann; David R Hinton; Stephen A Stohlman
Journal:  Front Immunol       Date:  2016-09-21       Impact factor: 7.561

Review 9.  Clinical Outlook for Type-1 and FOXP3(+) T Regulatory Cell-Based Therapy.

Authors:  Silvia Gregori; Laura Passerini; Maria-Grazia Roncarolo
Journal:  Front Immunol       Date:  2015-11-25       Impact factor: 7.561

Review 10.  Multiple Sclerosis: Mechanisms of Disease and Strategies for Myelin and Axonal Repair.

Authors:  Hernan Nicolas Lemus; Arthur E Warrington; Moses Rodriguez
Journal:  Neurol Clin       Date:  2018-02       Impact factor: 3.806
View more
  2 in total

1.  OBIF: an omics-based interaction framework to reveal molecular drivers of synergy.

Authors:  Jezreel Pantaleón García; Vikram V Kulkarni; Tanner C Reese; Shradha Wali; Saima J Wase; Jiexin Zhang; Ratnakar Singh; Mauricio S Caetano; Humam Kadara; Seyed Javad Moghaddam; Faye M Johnson; Jing Wang; Yongxing Wang; Scott E Evans
Journal:  NAR Genom Bioinform       Date:  2022-04-05

2.  Bezafibrate Enhances AAV Vector-Mediated Genome Editing in Glycogen Storage Disease Type Ia.

Authors:  Hye-Ri Kang; Lauren Waskowicz; Andrea M Seifts; Dustin J Landau; Sarah P Young; Dwight D Koeberl
Journal:  Mol Ther Methods Clin Dev       Date:  2019-02-10       Impact factor: 6.698
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.